Pierre Fabre Laboratories and the EspeRare Foundation to be honored with the EURORDIS Company Award for Patient Engagement 2024, in their approach to co-developing a treatment for XLHED.

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Pierre-Fabre-Esperare

More Like This

PR Newswire associated0

Pierre Fabre Laboratories, committed to combating rare pediatric diseases via innovative therapies

PR Newswire associated0

Pierre Fabre Laboratories receives the Galien International Prize for EBVALLO®, the first allogeneic immunotherapy for patients with a rare cancer

PR Newswire associated0

Pierre Fabre Laboratories and Vernalis announce a drug discovery collaboration in oncology

PR Newswire associated0

Pierre Fabre Laboratories and RedRidge Bio Announce a Drug Discovery and Co-development Partnership

PR Newswire associated0

Pierre Fabre Laboratories to accelerate their development in onco-hematology by acquiring the license for a breakthrough T-cell immunotherapy in North America

RegenLab France receives prestigious EU-EIB Innovation Champion Award. Antoine Turzi, CEO and Founder of RegenLab, pictured between two officials of the European Investment Bank. (Photo: Business Wire)

RegenLab France Receives Prestigious EU-EIB Innovation Champion Award

PR Newswire associated0

Chiesi Global Rare Diseases Launches New Research Grant Initiative to Support Research Excellence in Lysosomal Storage Disorders

The Oxford-Harrington Rare Disease Centre (OHC) Announces Inaugural 2024 Rare Disease Scholar Award Recipients